Correlation Between Medigen Biotechnology and Central Reinsurance

Can any of the company-specific risk be diversified away by investing in both Medigen Biotechnology and Central Reinsurance at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Medigen Biotechnology and Central Reinsurance into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Medigen Biotechnology and Central Reinsurance Corp, you can compare the effects of market volatilities on Medigen Biotechnology and Central Reinsurance and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Medigen Biotechnology with a short position of Central Reinsurance. Check out your portfolio center. Please also check ongoing floating volatility patterns of Medigen Biotechnology and Central Reinsurance.

Diversification Opportunities for Medigen Biotechnology and Central Reinsurance

0.49

Correlation Coefficient

Medigen Biotechnology  Central Reinsurance

Very weak diversification

The 3 months correlation between Medigen and Central is 0.49. Overlapping area represents the amount of risk that can be diversified away by holding Medigen Biotechnology and Central Reinsurance Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Central Reinsurance Corp and Medigen Biotechnology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Medigen Biotechnology are associated (or correlated) with Central Reinsurance. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Central Reinsurance Corp has no effect on the direction of Medigen Biotechnology i.e., Medigen Biotechnology and Central Reinsurance go up and down completely randomly.

Pair Corralation between Medigen Biotechnology and Central Reinsurance

Assuming the 90 days trading horizon Medigen Biotechnology is expected to under-perform the Central Reinsurance. In addition to that, Medigen Biotechnology is 1.58 times more volatile than Central Reinsurance Corp. It trades about -0.17 of its total potential returns per unit of risk. Central Reinsurance Corp is currently generating about 0.0 per unit of volatility. If you would invest  2,600  in Central Reinsurance Corp on September 29, 2024 and sell it today you would lose (10.00) from holding Central Reinsurance Corp or give up 0.38% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Medigen Biotechnology  vs.  Central Reinsurance Corp

Medigen Biotechnology

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Medigen Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in January 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

Central Reinsurance Corp

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Central Reinsurance Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Central Reinsurance is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors.

Pair Trading with Medigen Biotechnology and Central Reinsurance

The main advantage of trading using opposite Medigen Biotechnology and Central Reinsurance positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Medigen Biotechnology position performs unexpectedly, Central Reinsurance can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Central Reinsurance will offset losses from the drop in Central Reinsurance's long position.

The idea behind Medigen Biotechnology and Central Reinsurance Corp pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.